BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...
Earl Davis, head of fixed income at BMO Global Asset Management, shares his outlook on the BoC's upcoming rate decision as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback